Nasdaq gnlx.

Genelux press release (NASDAQ:GNLX): Q3 GAAP EPS of -$0.20 misses by $0.02. $29.9 million in cash and equivalents. Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage ...

Nasdaq gnlx. Things To Know About Nasdaq gnlx.

CIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ...Posted by Techdows on Nov 28th, 2023. HC Wainwright initiated coverage on shares of Genelux ( NASDAQ:GNLX – Free Report) in a research note issued to investors on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $35.00 target price on the stock. A number of other brokerages also recently …WebBack to GNLX Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ... GNLX Genelux Corporation Form 8-K - Current report. 0001231457 false 0001231457 2023-10-10 2023-10-10 iso4217:USD xbrli:shares ... Monitor; Level 2; Movers; Portfolio; Markets; Forums; Menu ...17. 4. 2023 ... Genelux President, CEO & Chairman Thomas Zindrick shares how being #NasdaqListed helps $GNLX reach its goals in improving the lives of the ...

The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 35.02 / share. This is an increase of 8.99% from the prior estimate of 32.13 dated August 31, 2023.Web

GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, representing a significant increase from its one-year low of $5.35 and a modest uptick from its impressive one-year high of $39.27. The stock’s 50-day simple moving average is currently resting at $26.83, indicating a positive trend that is grabbing the attention of expert market analysts.

Genelux Corporation (NASDAQ:GNLX) fell 8.1% to $5.65. Genelux announced pricing of $15 million initial public offering of 2.5 million shares of common stock at a price of $6 per share.WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ...Late clinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) announced a private placement of 1.67M shares at a price of $20 per share, for gross proceeds of approximately $33M.Proceeds from ...20. 11. 2023 ...Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […]

Jan 27, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history.

Nasdaq provides NLS Volume, Previous Close, Today's High & Low, and the 52 week High & Low. The intraday chart, the last-five real-time quotes and sales data. Real-time stock …

Clinical-stage immuno-oncology company, Genelux (NASDAQ:GNLX) said that Lourie S. Zak will join the company as CFO, effective August 28, 2023.Ms. Zak will join Genelux with an extensive background ...We explain how to buy Genelux Corporation Common Stock stock, compare the best stock trading platforms and use a detailed analysis to learn about (GNLX).Jul 6, 2023 · The average one-year price target for Genelux (NASDAQ:GNLX) has been revised to 32.13 / share. This is an increase of 80.00% from the prior estimate of 17.85 dated June 1, 2023. WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WebWESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...WebWESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO ...Web

Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Given GNLX’s positive Phase 2 trial results to-date, my outlook on IPO is a Buy for patient, risk-tolerant life science investors with a long-term hold time frame. ... (NASDAQ:GNLX) was founded ...Web1. 6. 2023 ... The stock jumped after the company released, late last week, positive phase 2 data on the its lead therapy. Expand. NASDAQ: GNLX. Genelux.GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...

WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...

About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Bed Bath & Beyond Inc. Common Stock. 1.74%.Genelux Corp. GNLX (U.S.: Nasdaq) Overview Profile Financials Income Statement Balance Sheet Cash Flow Research & Ratings Historical Prices Options Advanced Charting News Genelux Corp. No...View real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology …Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...Genelux Corporation (NASDAQ:GNLX) gained 10.5% to $5.02. Latham Group, Inc. (NASDAQ:SWIM) gained 10.2% to $3.7050 following Q4 results. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) rose 9.6% to $7.75 ...WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...

29. 3. 2023 ... is redefining immuno-oncology. $GNLX is a late clinical-stage biotechnology company focused on improving the lives of patients affected by ...

Aug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...

Nov 27, 2023 · WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ... Nov 29, 2023 · Genelux (NASDAQ:GNLX) PT Lowered to $30.00 americanbankingnews.com - November 25 at 3:58 AM: Genelux VP Sold $191K In Company Stock benzinga.com - November 23 at 12:58 PM: Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25% finance.yahoo.com - November 17 at 8:49 AM Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.WebFind the latest Earnings Report Date for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. Shares of Genelux Corporation (NASDAQ:GNLX) got a boost, shooting 24% to $36.67. Sea Limited (NYSE:SE) shares were also up, gaining 16% to $76.09 after the company reported better-than-expected Q4 ...NASDAQ does not use this value to determine compliance with the listing requirements. Inpixon Common Stock (INPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global ...WebCIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ...WebShares of Genelux Corporation (NASDAQ:GNLX) got a boost, shooting 24% to $36.67. Sea Limited (NYSE:SE) shares were also up, gaining 16% to $76.09 after the company reported better-than-expected Q4 ...

Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WebGenelux | 726 followers on LinkedIn. Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different versions of …Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Instagram:https://instagram. www mysmartmove com reviewstop financial advisors in san antoniomicrosoft share price historybias tire market About. Genelux Corporation, a Delaware · Highlight. A company researching a leading · Exchange. NASDAQ. Listing Date · NASDAQ. Listing Date. 01/26/2023.WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ... sequoia funds groupstock botz Genelux Corporation. WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical ...WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid … schwab offices Nov 18, 2023 · Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […] FN Media Group Presents USA News Group News Commentary . Vancouver, BC – October 11, 2023 – USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer …57.59%. Get the latest Genelux Corp (GNLX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …